Prevalence, severity and predictors of HOMA-estimated insulin resistance in diabetic and nondiabetic patients with end-stage renal disease

Journal of Nephrology

Volumn 19, Issue 5, 2006, Pages 607-612

  Bodlaj, Gerd ^a   Berg, Jörg ^a   Pichler, Robert ^a   Biesenbach, Georg ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

End stage renal disease; Homeostasis model assessment; Insulin resistance; Predictor; Type 2 diabetes

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DIET RESTRICTION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PREDICTOR VARIABLE; PREVALENCE; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; C-PEPTIDE; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; PREVALENCE; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 33947252156     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-34.
2. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-900.
3. Parving HO, Ritz E. Diabetic nephropathy. In Brenner BM, Levine S (Eds). The kidney (6th edn). Philadelphia: WB Saunders 2000; 1731.
4. National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39 (Suppl 2): S32-3.
5. US Renal Data System. USRDS 2001 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2001.
6. Biesenbach G, Hubmann R, Grafinger P, Stuby U, Eichbauer-Sturm G, Janko O. 5-year overall survival rates of uremic type 1 and type 2 diabetic patients in comparison with age-matched nondiabetic patients with end-stage renal disease from a single dialysis center from 1991 to 1997. Diabetes Care 2000; 23: 1860-2.
7. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002; 25: 1135-41.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
9. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22: 818-22.
10. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron 2001; 89: 348-9.
11. Nishimura M, Murase M, Hashimoto T, Kobayashi H, Yamazaki S, Imai R, Okino K, Fujita H, Inoue N, Takahashi H, Ono T. Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int 2006; 69: 553-9.
12. Ascaso JF, Romero P, Real JT, Lorente RI, Martinez-Valls J, Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003; 14: 101-6.
13. Attman PO, Alaupovic P, Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987; 32: 368-75.
14. Mittal SK, Kowalski E, Trenkle J, McDonough B, Halinski D, Devlin K, Boylan E, Flaster E, Maesaka JK. Prevalence of hypertension in a hemodialysis population. Clin Nephrol 1999; 51: 77-82.
15. Bergstrom J, Wang T, Lindholm B. Factors contributing to catabolism in end-stage renal disease patients. Miner Electrolyte Metab 1998; 24: 92-101.
16. Barzilay J, Freedland E. Inflammation and its association with glucose disorders and cardiovascular disease. Treat Endocrinol 2003; 2: 85-94.
17. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumor necrosis factor a and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300.
18. Bodlaj G, Berg J, Pichler R, Sailer T, Biesenbach G. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters. J Nephrol 2004; 17: 112-7.
19. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
20. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int 2003; 63 (Suppl): S65-8.
21. Hong SY, Yang DH. Insulin levels and fibrinolytic activity in patients with end-stage renal disease. Nephron 1994; 68: 329-33.
22. Leckstrom A, Bjorklund K, Permert J, Larsson R, Westermark P. Renal elimination of islet amyloid polypeptide. Biochem Biophys Res Commun 1997; 239: 265-8.
23. Hoekstra JB, van Rijn HJ, Erkelens DW, Thijssen JH. C-peptide. Diabetes Care 1982; 5: 438-46.
24. Lee P, O'Neal D, Murphy B, Best J. High density lipoprotein (HDL) particle composition in patients with end stage renal failure (ESRF) on chronic dialysis. Aust N Z J Med 1997; 27: 285-93.
25. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496-504.
26. Taskinen MR. Type 2 diabetes as a lipid disorder. Curr Mol Med 2005; 5: 297-308.
27. Kimoto E, Shoji T, Emoto M, Miki T, Tabata T, Okuno Y, Ishimura E, Inaba M, Nishizawa Y. Effect of diabetes on uremic dyslipidemia. J Atheroscler Thromb 2002; 9: 305-13.
28. Stewart KJ, Bacber AC, Turner K, Lim JG, Hees PS, Shapiro EP, Tayback M, Ouyang P. Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 2005; 28: 9-18.
29. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-71.
30. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyorala K, Salonen JT, Karhapaa P. Asymptomatic atberosclerosis and insulin resistance. Arterioscler Thromb Vasc Biol 1991; 11: 1069-76.
31. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary heart disease. Diabetologia 1996; 39: 1345-50.
32. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R; the IRAS Investigators. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809-17.
33. Inchiostro S, Bertoli G, Zanette G, Donadon V. Evidence of higher insulin resistance in NIDDM patients with ischemic heart disease. Diabetologia 1994; 37: 597-603.
34. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R, Falezza G, Muggeo M. Intimal-medial thickness of the carotid artery in nondiabetic and non-insulin-dependent diabetic subjects: relationship with insulin resistance. Diabetes Care 1997; 20: 627-31.